篇名 | 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis |
---|---|
卷期 | 39:4 |
作者 | Chun-Chieh Wang 、 Wei-Ting Chang 、 Yen-Hung Lin 、 Bing-Hsiean Tzeng 、 Ting-Hsing Chao 、 Chung-Lieh Hung 、 Yen-Wen Wu 、 Cheng-Hsuan Tsai 、 Wei-Wen Lin 、 Kuan-Cheng Chang 、 Hung-Yu Chang 、 Wen-Chung Yu 、 Wen-Hwa Wang 、 Cheng-I Cheng 、 Tzung-Dau Wang 、 Charles Jia-Yin Hou 、 Wen-Jone Chen |
頁次 | 511-543 |
關鍵字 | Amyloidosis 、 Cardiac 、 Heart failure 、 Hypertrophic cardiomyopathy 、 MEDLINE 、 Scopus 、 SCIE |
出刊日期 | 202307 |
DOI | 10.6515/ACS.202307_39(4).20230610A |
Cardiac amyloidosis is one form of systemic amyloidosis caused by abnormal amyloid fibrils deposited in the extracellular space of themyocardium causing heart failure because of restrictive cardiomyopathy and conduction disturbances. The incidence and prevalence of cardiac amyloidosis are higher than previously noted, particularly among special populations. The most common forms of cardiac amyloidosis are light chain and transthyretin amyloid cardiomyopathy. Even though more than 70% of patients with systemic amyloidosis have cardiac amyloidosis, the diagnosis is often delayed, suggesting significant gaps in the knowledge of cardiac amyloidosis and a lack of multidisciplinary teamwork in our daily practice. The Taiwan Society of Cardiology Heart Failure Committee organized experts to draft the “Expert Consensus on the diagnosis and treatment of cardiac amyloidosis.” This statement aims to help clinicians and healthcare professionals improve early diagnosis and management of cardiac amyloidosis in Taiwan. The expert panel met virtually to review the data and discuss the consensus statements. Our review provided practical information about diagnostic methods and algorithms, clinical clues and red-flag signs, cardiac amyloidosis per se and its comorbidities treatment modalities, and follow-up plans for asymptomatic transthyretin gene carriers. We especially innovate two acronyms, “HFpEF MUTED CALL” and “HFmrEF MUST COUNT”, to help in the early diagnosis and screening of transthyretin amyloid cardiomyopathy as shown in the Central Illustration.